Everolimus Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
This study is ongoing, but not recruiting participants.
Study NCT00410124
Information provided by Novartis
First Received: December 11, 2006
Last Updated: November 18, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
